Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson Sells 50,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total transaction of $421,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at $6,388,573.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Gibson also recently made the following trade(s):

  • On Wednesday, May 1st, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00.
  • On Wednesday, April 3rd, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.84, for a total transaction of $353,600.00.
  • On Thursday, March 28th, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.10, for a total transaction of $404,000.00.

Recursion Pharmaceuticals Trading Down 5.5 %

NASDAQ RXRX opened at $8.51 on Friday. The company has a 50 day moving average of $8.68 and a 200-day moving average of $9.72. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.97 and a 1-year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The firm had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The company’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RXRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Friday, May 10th. KeyCorp lifted their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th.

View Our Latest Research Report on RXRX

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. ARK Investment Management LLC lifted its holdings in Recursion Pharmaceuticals by 200.4% in the fourth quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after buying an additional 13,777,689 shares during the period. Mubadala Investment Co PJSC acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at $128,041,000. FMR LLC lifted its holdings in Recursion Pharmaceuticals by 134.4% in the third quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after buying an additional 6,129,935 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Recursion Pharmaceuticals by 161.2% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after buying an additional 5,680,656 shares during the period. Finally, Nikko Asset Management Americas Inc. lifted its holdings in Recursion Pharmaceuticals by 161.2% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock valued at $90,565,000 after buying an additional 5,680,656 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.